Author Index

Abraham, A.A. *see* Linde, K., 101
Abraham, E. and Robinson, A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia, 757
Abramovitz, A.S. *see* Mishkin, E.M., 147
Adami Lami, C. *see* Resti, M., 15
Ahonkhai, V.I., Lukacs, L.J., Jonas, L.C. and Calandra, G.B. Clinical experience with PedvaxHIB, a conjugate vaccine of *Haemophilus influenzae* type b polysaccharide – *Neisseria meningitidis* outer membrane protein, S38
Ajello, F., Lampiasi, A.M., Candido, G. and D'Angelo, C. Circulating diphtheria antitoxin levels in children aged 11–14 years in relation to the vaccinal history, 502
Akahane, Y. *see* Kuroda, S., 163
Alenius, S. *see* Carlsson, U., 577
Allison, A.C. *see* Byars, N.E., 309
Alm, R.A., Mayrhofer, G., Kotlarski, I. and Manning, P.A. Amino-terminal domain of the El Tor haemolysin of *Vibrio cholerae* O1 is expressed in classical strain and is cytotoxic, 588
Altaner, C., Ban, J., Altanerova, V. and Janik, V. Protective vaccination against bovine leukaemia virus infection by means of cell-derived vaccine, 889
Altanerova, V. *see* Altaner, C., 889
Altenburger, W. *see* Etlinger, H.M., 470
Amann, E. *see* Schorr, J., 675
Amara, D.A. *see* Chavez-Olortegui, C., 907
Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A-M., Caplan, B., Meyer, H.L. and Klein, M. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats, 505
Ameghino, E. *see* Tengerdy, R.P., 273
Amosenko, F.A., Svitkin, Y.V., Popova, V.D., Terletskaya, E.N., Timofeev, A.V., Elbert, L.B., Lashkevich, V.A. and Drozdov, S. Use of protamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines, 207
Anderson, A.O. *see* Anderson Jr, G.W., 710
Anderson Jr, G.W., Lee, J.O., Anderson, A.O., Powell, N., Mangiafico, J.A. and Meadors, G. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats, 710
André, F.E. *see* Ruuskanen, O., 117
Ansher, S., Thompson, W. and Habig, W. Vaccine-induced alterations in hepatic drug metabolism, 277
Aray, D.R. *see* Ronish, R.H., 364
Arnon, R. Review – Immuno-parasitological parameters in schistosomiasis – A perspective view of a vaccine-oriented immunochemist, 379
Arondel, J. *see* Sansonetti, P.J., 416
Aronson, N.E. *see* Ronish, R.H., 364
Arumugham, R. *see* Paradiso, P.R., 231
Arvilommi, H. *see* Kantele, A., 428
Arya, S.C. Spread of 'unconventional viruses' through sheep-brain rabies vaccines, 70
Arya, S.C. Statistical evaluation of working standards of oral polio vaccines and frequency distribution of titres beyond the fiducial limits, 604
Arya, S.C. Adjuvant therapy for non-responders to reduced doses of hepatitis B vaccine during infancy, 604
Arya, S.C. Enhancement of response to vaccines and immunomodulator through carboxy-vinylpolymer couples, 690
Åslund, L. *see* Sjölander, A., 443
Aubert, A. *see* Marciani, D.J., 89
Aulaqi, A.A. *see* Lifely, M.R., 60
Attridge, S. Oral immunization with *Salmonella typhi* Ty21a-based clones expressing *Vibrio cholerae* O-antigen: serum bactericidal antibody responses in man in relation to pre-immunization antibody levels, 877
Azad, A.A., McKern, N.M., Macreadie, I.G., Failla, P., Heine, H-G., Chapman, A., Ward, C.W. and Fahey, K. Physicochemical and immunological characterization of recombinant host-protective antigen (VP2) of infectious bursal disease virus, 715
Azzari, C. *see* Resti, M., 15

Baer, G.M. *see* Chutivongse, S., 573
Baer, G.M. *see* Wunderli, P.S., 638
Balayan, M.S. *see* Kusov, Y.Y., 540
Balayan, S.S. *see* Stanislavsky, E.S., 491
Ballantine, S.P. *see* Romanos, M.A., 901
Baltazar, R.S. *see* Blancou, J., 432
Ban, J. *see* Altaner, C., 889
Barnard, A.L. *see* Page, M., 47
Barnett, P.V. *see* Brown, A.L., 595
Barone, P. *see* Giammanco, G., 747
Barteling, S.J. and Vreeswijk, J. Developments in foot-and-mouth disease vaccines, 75
Bautista, C.F. *see* Fishbein, D.B., 581
Beer, J. *see* Linde, K., 101
Beesley, K.M. *see* Romanos, M.A., 901
Behnke, R.H. *see* Russell, D.W., 691
Bellanti, J.A. *see* Hooke, A.M., 238
Beltz, G.A. *see* Marciani, D.J., 89
Bender, B.S. *see* Meitin, C.A., 751
Ben-Ephraim, S. Use of glutaraldehyde for preparation of immunogenic compounds, 913
Bengounia, A. *see* Relyveld, E., 369
Bennett, M. *see* Lai, W.C., 177
Berencsi, K. *see* Gönczöl, E., 631
Berinstein, A., Piatti, P., Gaggino, O.P., Schudel, A.A. and Sadir, A.M. Enhancement of the immune response elicited with foot-and-mouth disease virus vaccines by an extract of the *Mycobacterium* sp. wall, 883
Bernard, K.W. and Fishbein, D.B. Pre-exposure rabies prophylaxis for travellers: are the benefits worth the cost?, 833
Bernardini, M.L. *see* Sansonetti, P.J., 416
Bertolino, P. *see* Gardnier, F., 340
Berzins, K. *see* Sjolander, A., 443
Bielefeldt Ohmann, H., McDougall, L. and Potter, A. Secondary *in vitro* B lymphocyte (antibody) response to microbial antigens: use in appraisal of vaccine immunogenicity and cytokine immunoregulation, 170
Bijlmer, H.A. World-wide epidemiology of *Haemophilus influenzae* meningitis; industrialized versus non-industrialized countries, S5
Bilancia, G.G. *see* Giammanco, G., 747
Biswas, S. and Sharma, Y.D. Human response to a malaria vaccine candidate antigen, 467
Bizzini, B. *see* Fattal-German, M., 542
Blancou, J., Soria Baltazar, R., Molli, I. and Stoltz, J.F. Effective postexposure treatment of rabies-infected sheep with rabies immune globulin and vaccine, 432
Bock, H.L. *see* Klockmann, U., 42
Bogaerts, H. *see* Ruuskanen, O., 117
Bonneau, A-M. *see* Ambrose, M.W., 505
Boscia, J.A. *see* Bush, L., 807
Boslego, J.W., Tramont, E.C., Chung, R.C., McChesney, D.G., Ciak, J., Sadoff, J.C., Piziak, M.V., Brown, J.D., Brinton Jr, C.C. and Wood, S.W. Efficacy trial of a parenteral gonococcal pilus vaccine in men, 154
Böttiger, M. *see* Christenson, B., 326
Bourhy, H. *see* Perrin, P., 549
Bozzola, J. *see* Thapar, M.A., 129
Brideau, R.J. and Wathen, M.W. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice, 863
Brinton Jr, C.C. *see* Boslego, J.W., 154
Brown, A.L., Francis, M.J., Hastings, G.Z., Parry, N.R., Barnett, P.V., Rowlands, D.J. and Clarke, B.E. Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted, 595
Brown, E.G., Furesz, J., Dimock, K., Yarosh, W. and Contreras, G. Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients, 840
Brown, J.D. *see* Boslego, J.W., 154
Budowsky, E.I. and Zalesskaya, M.A. Principles of selective inactivation of viral gemone. V. Rational selection of conditions for inactivation of the viral

Author Index

Abraham, A.A. *see* Linde, K., 101
Abraham, E. and Robinson, A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia, 757
Abramovitz, A.S. *see* Mishkin, E.M., 147
Adami Lami, C. *see* Resti, M., 15
Ahonkhai, V.I., Lukacs, L.J., Jonas, L.C. and Calandra, G.B. Clinical experience with PedvaxHIB, a conjugate vaccine of *Haemophilus influenzae* type b polysaccharide – *Neisseria meningitidis* outer membrane protein, S38
Ajello, F., Lampiasi, A.M., Candido, G. and D'Angelo, C. Circulating diphtheria antitoxin levels in children aged 11–14 years in relation to the vaccinal history, 502
Akahane, Y. *see* Kuroda, S., 163
Alenius, S. *see* Carlsson, U., 577
Allison, A.C. *see* Byars, N.E., 309
Alm, R.A., Mayrhofer, G., Kotlarski, I. and Manning, P.A. Amino-terminal domain of the El Tor haemolysin of *Vibrio cholerae* O1 is expressed in classical strain and is cytotoxic, 588
Altaner, C., Ban, J., Altanerova, V. and Janik, V. Protective vaccination against bovine leukaemia virus infection by means of cell-derived vaccine, 889
Altanerova, V. *see* Altaner, C., 889
Altenburger, W. *see* Etlinger, H.M., 470
Amann, E. *see* Schorr, J., 675
Amara, D.A. *see* Chavez-Olortegui, C., 907
Ambrose, M.W., Wyde, P.R., Ewasyshyn, M., Bonneau, A-M., Caplan, B., Meyer, H.L. and Klein, M. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats, 505
Ameghino, E. *see* Tengerdy, R.P., 273
Amosenko, F.A., Svitkin, Y.V., Popova, V.D., Terletskaya, E.N., Timofeev, A.V., Elbert, L.B., Lashkevich, V.A. and Drozdov, S. Use of protamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines, 207
Anderson, A.O. *see* Anderson Jr, G.W., 710
Anderson Jr, G.W., Lee, J.O., Anderson, A.O., Powell, N., Mangiafico, J.A. and Meadors, G. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats, 710
André, F.E. *see* Ruuskanen, O., 117
Ansher, S., Thompson, W. and Habig, W. Vaccine-induced alterations in hepatic drug metabolism, 277
Aray, D.R. *see* Ronish, R.H., 364
Arnon, R. Review – Immuno-parasitological parameters in schistosomiasis – A perspective view of a vaccine-oriented immunochemist, 379
Arondel, J. *see* Sansonetti, P.J., 416
Aronson, N.E. *see* Ronish, R.H., 364
Arumugham, R. *see* Paradiso, P.R., 231
Arvilommi, H. *see* Kantele, A., 428
Arya, S.C. Spread of 'unconventional viruses' through sheep-brain rabies vaccines, 70
Arya, S.C. Statistical evaluation of working standards of oral polio vaccines and frequency distribution of titres beyond the fiducial limits, 604
Arya, S.C. Adjuvant therapy for non-responders to reduced doses of hepatitis B vaccine during infancy, 604
Arya, S.C. Enhancement of response to vaccines and immunomodulator through carboxy-vinylpolymer couples, 690
Åslund, L. *see* Sjölander, A., 443
Aubert, A. *see* Marciani, D.J., 89
Aulaqi, A.A. *see* Lifely, M.R., 60
Attridge, S. Oral immunization with *Salmonella typhi* Ty21a-based clones expressing *Vibrio cholerae* O-antigen: serum bactericidal antibody responses in man in relation to pre-immunization antibody levels, 877
Azad, A.A., McKern, N.M., Macreadie, I.G., Failla, P., Heine, H-G., Chapman, A., Ward, C.W. and Fahey, K. Physicochemical and immunological characterization of recombinant host-protective antigen (VP2) of infectious bursal disease virus, 715
Azzari, C. *see* Resti, M., 15

Baer, G.M. *see* Chutivongse, S., 573
Baer, G.M. *see* Wunderli, P.S., 638
Balayan, M.S. *see* Kusov, Y.Y., 540
Balayan, S.S. *see* Stanislavsky, E.S., 491
Ballantine, S.P. *see* Romanos, M.A., 901
Baltazar, R.S. *see* Blancou, J., 432
Ban, J. *see* Altaner, C., 889
Barnard, A.L. *see* Page, M., 47
Barnett, P.V. *see* Brown, A.L., 595
Barone, P. *see* Giammanco, G., 747
Barteling, S.J. and Vreeswijk, J. Developments in foot-and-mouth disease vaccines, 75
Bautista, C.F. *see* Fishbein, D.B., 581
Beer, J. *see* Linde, K., 101
Beesley, K.M. *see* Romanos, M.A., 901
Behnke, R.H. *see* Russell, D.W., 691
Bellanti, J.A. *see* Hooke, A.M., 238
Beltz, G.A. *see* Marciani, D.J., 89
Bender, B.S. *see* Meitin, C.A., 751
Ben-Ephraim, S. Use of glutaraldehyde for preparation of immunogenic compounds, 913
Bengounia, A. *see* Relyveld, E., 369
Bennett, M. *see* Lai, W.C., 177
Berencsi, K. *see* Gönczöl, E., 631
Berinstein, A., Piatti, P., Gaggino, O.P., Schudel, A.A. and Sadir, A.M. Enhancement of the immune response elicited with foot-and-mouth disease virus vaccines by an extract of the *Mycobacterium* sp. wall, 883
Bernard, K.W. and Fishbein, D.B. Pre-exposure rabies prophylaxis for travellers: are the benefits worth the cost?, 833
Bernardini, M.L. *see* Sansonetti, P.J., 416
Bertolino, P. *see* Gardnier, F., 340
Berzins, K. *see* Sjolander, A., 443
Bielefeldt Ohmann, H., McDougall, L. and Potter, A. Secondary *in vitro* B lymphocyte (antibody) response to microbial antigens: use in appraisal of vaccine immunogenicity and cytokine immunoregulation, 170
Bijlmer, H.A. World-wide epidemiology of *Haemophilus influenzae* meningitis; industrialized versus non-industrialized countries, S5
Bilancia, G.G. *see* Giammanco, G., 747
Biswas, S. and Sharma, Y.D. Human response to a malaria vaccine candidate antigen, 467
Bizzini, B. *see* Fattal-German, M., 542
Blancou, J., Soria Baltazar, R., Molli, I. and Stoltz, J.F. Effective postexposure treatment of rabies-infected sheep with rabies immune globulin and vaccine, 432
Bock, H.L. *see* Klockmann, U., 42
Bogaerts, H. *see* Ruuskanen, O., 117
Bonneau, A-M. *see* Ambrose, M.W., 505
Boscia, J.A. *see* Bush, L., 807
Boslego, J.W., Tramont, E.C., Chung, R.C., McChesney, D.G., Ciak, J., Sadoff, J.C., Piziak, M.V., Brown, J.D., Brinton Jr, C.C. and Wood, S.W. Efficacy trial of a parenteral gonococcal pilus vaccine in men, 154
Böttiger, M. *see* Christenson, B., 326
Bourhy, H. *see* Perrin, P., 549
Bozzola, J. *see* Thapar, M.A., 129
Brideau, R.J. and Wathen, M.W. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice, 863
Brinton Jr, C.C. *see* Boslego, J.W., 154
Brown, A.L., Francis, M.J., Hastings, G.Z., Parry, N.R., Barnett, P.V., Rowlands, D.J. and Clarke, B.E. Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted, 595
Brown, E.G., Furesz, J., Dimock, K., Yarosh, W. and Contreras, G. Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients, 840
Brown, J.D. *see* Boslego, J.W., 154
Budowsky, E.I. and Zalesskaya, M.A. Principles of selective inactivation of viral gemone. V. Rational selection of conditions for inactivation of the viral

suspension infectivity to a given extent by the action of β-propiolactone, 319
Budowsky, E.I., Friedman, E.A., Zheleznova, N.V. and Noskov, E.S. Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of β-propiolactone, 398
Budowsky, E.I., Friedman, E.A. and Zheleznova, N.V. Principles of selective inactivation of viral genome. VII. Some peculiarities in determination of viral suspension infectivity during inactivation by chemical agents, 473
Bujard, H. *see* von Brunn, A., 477
Buongiorno, R. *see* Dentico, P., 438
Burny, A. *see* Portetelle, D., 194
Bush, L., Moonsammy, G.I. and Boscia, J.A. Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another, 807
Buynitzky, S. *see* Hunter, R., 250
Buysse, J.M. *see* Venkatesan, M., 358
Byars, N.E., Nakano, G., Welch, M., Lehman, D. and Allison, A.C. Improvement of hepatitis B vaccine by the use of a new adjuvant, 309

Calandra, G. *see* Miskovsky, E., 346
Calandra, G.B. *see* Ahonkhai, V.I., S38
Calasso, A. *see* Dentico, P., 438
Camba, R.A. *see* Fishbein, D.B., 581
Cameron, D.J. *see* Russell, D.W., 691
Candido, G. *see* Ajello, F., 502
Capiau, C. *see* Ruuskanen, O., 117
Caplan, B. *see* Ambrose, M.W., 505
Carlos, E.T. *see* Fishbein, D.B., 581
Carlsson, U., Alenius, S. and Sundquist, B. Protective effect of an ISCOM bovine virus diarrhoea virus (BVDV) vaccine against an experimental BVDV infection in vaccinated and non-vaccinated pregnant ewes, 577
Carpenter, L. *see* Morrill, J.C., 35
Cerquetti, M.C. *see* Hooke, A.M., 238, 294
Chaicumpa, W. *see* Chongsa-nguan, M., 53
Chambon, P. *see* Hareuveni, M., 618
Chan, C-Y., Lee, S-D., Tsai, Y-T. and Lo, K-J. Booster response to recombinant yeast-derived hepatitis B in vaccinees whose anti-HBs responses were initially elicited by a plasma-derived vaccine, 765
Chang, M-H. *see* Lin, H-H., 457
Chapman, A. *see* Azad, A.A., 715
Charles, I.G. *see* Romanos, M.A., 901
Chatfield, S. *see* Hone, D.M., 810
Chatfield, S.N. *see* Jones, P.W., 29
Chaud, P. *see* Teulieres, L., 521
Chavez-Olortegui, C., Amara, D.A., Rochat, H., Diniz, C. and Granier, C. *In vivo* protection against Scorpion toxins by liposomal immunization, 907
Chen, D-S. *see* Lin, H-H., 457
Chen, R.T., Moses, J.M., Markowitz, L.E. and Orenstein, W.A. Adverse events following measles–mumps–rubella and measles vaccinations in college students, 297
Chengalvala, M., Lubeck, M.D., Davis, A.R., Mizutani, S., Molnar-Kimber, K., Morin, J. and Hung, P.P. Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs, 485
Chiaramonte, M. *see* Chiarini, A., 837
Chiarini, A., Giammanco, A., Stroffolini, T., De Mattia, D., Masia, M.D., Sarzana, A., Taormina, S., Maggio, M., Rigo, G., Chiaramonte, M., Trivello, R. and Scarpa, B. Immunity to diphtheria in the 3–19 year age group in Italy, 837
Chiewbamrungkiat, M. *see* Tepsumethanon, W., 627
Chongsa-nguan, M., Chaicumpa, W., Ruangkunaporn, Y. and Looareesuwan, S. Immunogenicity of two formulations of oral cholera vaccines in Thai volunteers, 53
Christenson, B. and Böttiger, M. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule, 326
Chung, R.C. *see* Boslego, J.W., 154
Chutivongse, S. *see* Tepsumethanon, W., 627
Chutivongse, S., Wilde, H., Fishbein, D.B., Baer, G.M. and Hemachudha, T. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine, 573
Ciak, J. *see* Boslego, J.W., 154
Cihlova, V. *see* Klockmann, U., 42
Clare, J.J. *see* Romanos, M.A., 901
Clarke, B.E. *see* Brown, A.L., 595
Clements, M.L. *see* Miskovsky, E., 346
Cleverly, A. *see* Lifely, M.R., 60
Cohen, N. *see* Siber, G.R., 735
Cohen, S. *see* Grosfeld, H., 451
Coleman, P.J., Shaw Jr, F.E., Serovich, J., Hadler, S.C. and Margolis, H.S. Intradermal hepatitis B vaccination in a large hospital employee population, 723
Collins, P. *see* Jones, P.W., 29
Collins, P.L. *see* Murphy, B.R., 185
Contreras, G. *see* Brown, E.G., 840
Cooper, P.D. and Steele, E.J. Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and in vitro properties, 351
Cooper, P.D., McComb, C. and Steele, E.J. The adjuvanticity of Algammulin, a new vaccine adjuvant, 408
Coursaget, P. *see* Relyveld, E., 843
Cristófani, L.M., Weinberg, A., Peixoto, V., Villas Boas, L.S., Souza Marques, H.H., Maluf Jr, P.T., Pannuti, C., Oselka, G.W., Neto, V.A. and Odone-Filho, U. Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy, 873
Cronier, J. *see* Marciani, D.J., 89
Cupps, T. *see* Miskovsky, E., 346

D'Angelo, C. *see* Ajello, F., 502
Datta, P. *see* Takayama, K., 257
Davis, A.R. *see* Chengalvala, M., 485
Davis, S.S. *see* O'Hagan, D.T., 768
De Magistris, M.R. *see* Podda, A., 741
De Mattia, D. *see* Chiarini, A., 837
Delem, A. *see* Ruuskanen, O., 117
Dentico, P., Zavoianni, A., Volpe, A., Buongiorno, R., Palma, R., Calasso, A., Pastore, G. and Schiraldi, O. Hepatitis B virus infection in hospital staff: epidemiology and persistence of vaccine-induced antibodies, 438
Desmettre, P. *see* Taylor, J., 190
Desmettre, P. *see* Portetelle, D., 194
Devillier, P. *see* Soulié, J.C., 545
d'Hauteville, H. *see* Sansonetti, P.J., 416
Di Marchi, R.D. *see* Kit, M., 564
Di Tommaso, A. *see* Podda, A., 741
DiMarchi, R.D. *see* Mulcahy, G., 19
Dietzschold, B. *see* Tollis, M., 134
Dilger, P. *see* Page, M., 47
Dimock, K. *see* Brown, E.G., 840
Diniz, C. *see* Chavez-Olortegui, C., 907
Diniega, B.M. *see* Ronish, R.H., 364
Diouf, M.A. *see* Teulieres, L., 521
Dobbins, J.G. *see* Fishbein, D.B., 581
Dockrell, H. *see* Fine, P., 291
Doel, T.R. *see* Mulcahy, G., 19
Donachie, W. *see* Gilmour, N.J.L., 137
Donati, D. *see* Podda, A., 741
Dott, K. *see* Hareuveni, M., 618
Dougan, G. *see* Jones, P.W., 29
Dougan, G. *see* Hone, D.M., 810
Dougan, G. *see* Romanos, M.A., 901
Drozdov, S.G. *see* Amosenko, F.A., 207
Drozdov, S.G. *see* Kusov, Y.Y., 540
Dubray, G. *see* Jacques, I., 559, 896
Dunaevski, O.A. *see* Kusov, Y.Y., 540

Edelman, R. Perspective on the development of vaccines against Lyme disease, 531
Edvabnaya, L.S. *see* Stanislavsky, E.S., 491
Elbert, L.B. *see* Amosenko, F.A., 207
Elbert, L.B. *see* Kusov, Y.Y., 540
Ellis, R. *see* Miskovsky, E., 346
Ellis, R.W. *see* Vella, P.P., S26
Ellis, R.W. *see* Provost, P.J., 111
Endo, K. *see* Kameoka, J., 605
Erturk, M., Jennings, R., Phillpotts, R.J. and Potter, C.W. Biochemical characterization of herpes simplex virus type-1-immunostimulating complexes (ISCOMs): a multi-glycoprotein structure, 668
Erturk, M., Phillpotts, R.J., Welch, M.J. and Jennings, R. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection, 728
Esdaile, J. *see* Lifely, M.R., 60
Eskola, J., Takala, A., Käyhty, H., Peltola, H. and Mäkelä, P.H. Experience in Finland with *Haemophilus influenzae* type b vaccines, S14

Etlinger, H.M. and Altenburger, W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus, 470
Etlinger, H.M. and Knorr, R. Model using a peptide with carrier function for vaccination against different pathogens, 512
Ewasyshyn, M. *see* Ambrose, M.W., 505

Fahey, J.R. *see* Mishkin, E.M., 147
Fahey, K.J. *see* Azad, A.A., 715
Failla, P. *see* Azad, A.A., 715
Fairweather, N.F. *see* Romanos, M.A., 901
Fattal-German, M., Taillandier, J., Mathieu, D. and Bizzini, B. Pneumococcal vaccination of elderly individuals, 542
Fernandez-Prada, C. *see* Venkatesan, M., 358
Fescharek, R., Schwarz, S., Quast, U., Gandhi, N. and Karkhanis, S. Post-exposure prophylaxis: when the guidelines are not respected, 868
Fine, P. and Dockrell, H. Leprosy vaccines, 291
Fishbein, D.B. *see* Chutivongse, S., 573
Fishbein, D.B. *see* Bernard, K.W., 833
Fishbein, D.B., Miranda, N.J., Merrill, P., Camba, R.A., Meltzer, M., Carlos, E.T., Bautista, C.F., Sopungco, P.V., Mangahas, L.C., Hernandez, L.H., Leoncio, M.M, Mercado, D., Gregorio, S., Salva, E., Dobbins, J.G. and Winkler, W.G. Rabies control in the Republic of the Philippines: benefits and costs of elimination, 581
Fitzgerald, T.J. Syphilis vaccine: up-regulation of immunogenicity by cyclophosphamide, Ribi adjuvant, and indomethacin confers significant protection against challenge infection in rabbits, 266
Flores, J. *see* Vesikari, T., 334
Foged, N.T. Detection of stable epitopes on formaldehyde-detoxified *Pasteurella multocida* toxin by monoclonal antibodies, 817
Fontaine, A. *see* Sansonetti, P.J., 416
Forest, B.D. and LaBrooy, J.T. *In vivo* evidence of immunological masking of the *Vibrio cholerae* O antigen of a hybrid *Salmonella typhi* Ty21a–*Vibrio cholerae* oral vaccine in humans, 515
Formal, S.B. *see* Venkatesan, M., 358
Forquet, F. *see* Garnier, F., 340
Foster, T.J. Potential for vaccination against infections caused by *Staphylococcus aureus*, 221
Francis, M.J. *see* Brown, A.L., 595
Friedman, A. Induction of immune response to protein antigens by subcutaneous co-injection with water-miscible vitamin A derivatives, 122
Friedman, E.A. *see* Budowsky, E.I., 398, 473
Fritzell, C. *see* Perrin, P., 549
Früh, K. *see* von Brunn, A., 477
Fujisawa, Y. *see* Kuroda, S., 163
Fultz, P. Are we detouring from a direct route to development of HIV vaccines?, 783
Furesz, J. *see* Brown, E.G., 840
Furukawa, T. *see* Kameoka, J., 605

Gaggino, O.P. *see* Berinstein, A., 883
Gale, C. *see* Mulcahy, G., 19
Gale, C. *see* Kit, M., 564
Gandhi, N. *see* Fescharek, R., 868
Ganguly, R. *see* Russell, D.W., 691
Gardner, M. SIV vaccines: current status. The role of the SIV-macaque model in AIDS research, 787
Garnier, F., Forquet, F., Bertolino, P. and Gerlier, D. Enhancement of *in vivo* and *in vitro* T cell response against measles virus haemagglutinin after its incorporation into liposomes: effect of the phospholipid composition, 340
Gautier, C. *see* Hareuveni, M., 618
Gerlier, D. *see* Garnier, F., 340
Gershman, K. *see* Miskovsky, E., 346
Ghirga, G., Ghirga, P., Rodinò, P. and Presti, A. Safety of the subunit vaccine in asthmatic children, 913
Ghirga, P. *see* Ghirga, A., 913
Giammanco, A. *see* Chiarini, A., 837
Giammanco, G., Li Volti, S., Mauro, L., Bilancia, G.G., Salemi, I., Barone, P. and Musumeci, S. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy, 747
Gilbert, G.L. Epidemiology of *Haemophilus influenzae* type b disease in Australia and New Zealand, S10
Gilmour, J.S. *see* Gilmour, N.J.L., 137
Gilmour, N.J.L., Donachie, W., Sutherland, A.D., Gilmour, J.S., Jones, G.E. and Quirie, M. Vaccine containing iron-regulated proteins of *Pasteurella haemolytica* A2 enhances protection against experimental pasteurellosis in lambs, 137
Girard, M., The challenge of HIV vaccines, 781
Gizurarson, S., Tamura, S., Kurata, T., Hasioguchi, K. and Ogawa, H. The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane, 825
Gönczöl, E., deTaisne, C., Hirka, G., Berencsi, K., Lin, W., Paoletti, E. and Plotkin, S. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia–gB recombinant: the importance of the gB protein in HCMV immunity, 631
Gontier, C. *see* Perrin, P., 549
Goudeau, A. *see* Soulié, J.C., 545
Granato, C. *see* Levi, G.C., 216
Granier, C. *see* Chavez-Olortegui, C., 907
Granoff, D.M. and Holmes, S.J. Comparative immunogenicity of *Haemophilus influenzae* type b polysaccharide–protein conjugate vaccines, S30
Green, K. *see* Vesikari, T., 334
Gregorio, S. *see* Fishbein, D.B., 581
Grishina, G.K. *see* Kusov, Y.Y., 540
Grosfeld, H., Velan, B., Leitner, M., Lustig, S., Lachi, B-E., Cohen, S. and Shafferman, A. Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus, 451
Grosheide, P.M., van Osand, H.C., Schalm, S.W. and Heitjink, R.A. Immunoprophylaxis to limit a hepatitis B epidemic among women undergoing *in vitro* fertilization, 682
Gudding, R. *see* Øvernes, G., 25
Guellier, M. *see* Soulié, J.C., 545
Guerin, N. *see* Relyveld, E., 843
Guess, H.A. *see* Kuter, B.J., 643
Guillemin, F. *see* Taylor, J., 190
Gupta, C.K. *see* Sokhey, J., 69
Gupta, R.K., Misra, C.N., Gupta, V.K. and Saxena, S.N. An efficient method for production of purified inactivated Japanese encephalitis vaccine from mouse brains, 865
Gupta, R.K. and Relyveld, E.H. Adverse reactions after injection of adsorbed diphtheria–pertussis–tetanus (DPT) vaccine are not due only to pertussis organisms or pertussis components in the vaccine, 699
Gupta, R.K. *see* Relyveld, E., 843
Gupta, R.K. *see* Sokhey, J., 69
Gupta, R.K., Saxena, S.N., Sharm, S.B. and Ahuja, S. Comparison of cyclodextrin solid medium containing blood with Bordet–Gengou medium for growth of *Bordetella pertussis* phase 1 organisms, 215
Gupta, R.K. Detoxification of *Bordetella pertussis* organisms or pertussis toxin with glutaraldehyde for preparation of pertussis vaccine, 690
Gupta, V.K. *see* Gupta, R.K., 865

Habig, W. *see* Ansher, S., 277
Hadler, S.C. *see* Coleman, P.J., 723
Hagstedt, M. *see* Sjölander, A., 443
Hale, T.L. *see* Venkatesan, M., 358
Hall, S.L., Murphy, B.R. and van Wyke Coelingh, K.L. Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus, 659
Hammond, G., Parker, J., Mimms, L., Tate, R., Sekla, L. and Minuk, G. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines, 97
Hansson, M. *see* Sjölander, A., 443
Hareuveni, M., Wreschner, D.H., Kieny, M.P., Dott, K., Gautier, C., Tomasetto, C., Keydar, I., Chambon, P. and Lathe, R. Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA), 618
Harris, A.M. *see* Hone, D.M., 810
Hasioguchi, K. *see* Gizurarson, S., 825
Hastings, G.Z. *see* Brown, A.L., 595

Hayward, C. *see* Jones, P.W., 29
Heine, H-G. *see* Azad, A.A., 715
Heitjink, R.A. *see* Grosheide, P.M., 682
Hem, S.L. *see* Seeber, S.J., 201
Hemachudha, T. *see* Chutivongse, S., 573
Hemachudha, T. *see* Tepsumethanon, W., 627
Henrickson, K.J., Kingsbury, D.W., van Wyke Coelingh, K.L., Naeve, C.W. and Portner, A. Neutralizing epitopes of human parainfluenza virus type 3 are conformational and cannot be imitated by synthetic peptides, 243
Herder, C. *see* Quast, U., 228
Hernandez, L.H. *see* Fishbein, D.B., 581
Herzog, L. *see* Siber, G.R., 735
Hesley, T. *see* Miskovsky, E., 346
Hildreth, S. *see* Paradiso, P.R., 231
Hildreth, S.W. *see* Murphy, B.R., 185
Hilfenhaus, J. *see* Klockman, U., 210
Hillion, A.M. *see* Soulié, J.C., 545
Hirka, G. *see* Gönczöl, E., 631
Hoke, C.H. *see* Ronish, R.H., 364
Holmes, S.J. *see* Granoff, D.M., S30
Hone, D.M., Harris, A.M., Chatfield, S., Dougan, G. and Levine, M.M. Construction of genetically defined double *aro* mutants of *Salmonella typhi*, 810
Hong, K-H. *see* Lin, H-H., 457
Hooke, A.M., Wang, Z., Cerquetti, M.C. and Bellanti, J.A. Immunization with temperature-sensitive mutants of *Salmonella typhi* induces protection in mice, 238
Hooke, A.M., Cerquetti, M.C., Wan, K.S., Wang, Z., Sordelli, D.O. and Bellanti, J.A. Oral immunization of mice with temperature-sensitive *Pseudomonas aeruginosa* enhances pulmonary clearance of the wild-type, 294
Hu, B.T. *see* Paradiso, P.R., 231
Huchet, J. *see* Soulié, J.C., 545
Huet, M. *see* Relyveld, E., 369, 843
Hughey, D.F. *see* Mufson, M.A., 403
Hundt, E. *see* Schorr, J., 675
Hung, C. *see* Marciani, D.J., 89
Hung, P.P. *see* Chengalvala, M., 485
Hunter, R., Olsen, M. and Buynitzky, S. Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody, 250
Hunter, R.L. *see* Takayama, K., 257

Iino, S. *see* Kuroda, S., 163
Ioli, V. *see* Miskovsky, E., 346
Iorio, A.M. *see* Zei, T., 613
Iwarson, S. Strategies for immunization against invasive *Haemophilus influenzae* type b infection, S35

Jacques, I. and Dubray, G. *Escherichia hermannii* (ATCC 33651) polysaccharide-protein conjugates: comparison of two conjugation methods for the induction of humoral responses in mice, 559
Jacques, I., Olivier-Bernardin, V. and Dubray, G. Induction of antibody and protective responses in mice by *Brucella* O-polysaccharide–BSA conjugate, 896
Janik, V. *see* Altaner, C., 889
Jayakumar, R. and Ramadass, P. Immunoglobulin response to rabies virus immunization in dogs, 611
Jean-Francois, M.J.B. *see* Poskitt, D.C., 792
Jeffery, H. *see* O'Hagan, D.T., 768
Jennings, R. *see* Erturk, M., 668, 728
Joffret, M-L. *see* Perrin, P., 549
Johansson, B.E. and Kilbourne, E.D. Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine, 330
Jonas, L.C. *see* Ahonkhai, V.I., S38
Jones, G.E. *see* Gilmour, N.J.L., 137
Jones, P.W., Dougan, G., Hayward, C., Mackensie, N., Collins, P. and Chatfield, S.N. Oral vaccination of calves against experimental salmonellosis using a double *aro* mutant of *Salmonella typhimurium*, 29

Kameoka, J., Endo, K., Yoshinaga, K., Shiobara, S., Mopri, T., Matsuda, T. and Furukawa, T. Failure to induce cytomegalovirus immunity with its envelope antigen injected without adjuvants, 605
Kantele, A. and Mäkelä, P.H. Different profiles of the human immune response to primary and secondary immunization with an oral *Salmonella typhi* Ty21a vaccine, 423
Kantele, A., Kantele, J.M., Arvilommi, H. and Mäkelä, P.H. Active immunity is seen as a reduction in the cell response to oral live vaccine, 428
Kantele, J.M. *see* Kantele, A., 428
Kapikian, A.Z. *see* Vesikari, T., 334
Karkhanis, S. *see* Fescharek, R., 868
Kataoka, T., Kinomoto, M., Takegawa, M. and Tokunaga, T. Effect of a synthetic adjuvant for inducing anti-tumour immunity, 300
Kawaoka, Y. *see* Webster, R.G., 303
Käyhty, H. *see* Eskola, J., S14
Kehoe, M.A., Group A streptococcal antigens and vaccine potential, 797
Kelley, P.W. *see* Ronish, R.H., 364
Kensil, C.R. *see* Marciani, D.J., 89
Keydar, I. *see* Hareuveni, M., 618
Keystone Center, The. Final report of the Keystone AIDS vaccine liability project, 703
Kharin, N.V. *see* Kusov, Y.Y., 540
Khawplod, P. *see* Tepsumethanon, W., 627
Kieny, M.P. *see* Hareuveni, M., 618
Kilbourne, E.D. *see* Johansson, B.E., 330
Kingsbury, D.W. *see* Henrickson, K.J., 243
Kino, Y. *see* Mishkin, E.M., 147
Kinomoto, M. *see* Kataoka, T., 300
Kit, M., Kit, S., Little, S.P., Di Marchi, R.D. and Gale, C. Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes, 564
Kit, S. *see* Kit, M., 564
Klein, M. *see* Ambrose, M.W., 505
Klein, R.J. *see* Mishkin, E.M., 147
Klockmann, U., Bock, H.L., Kwasny, H., Praus, M., Cihlová, V., Tomková, E. and Křivanec, K. Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization, 42
Klockmann, I., Křivanec, K., Stephenson, J.R. and Hilfenhaus, J. Protection against European isolates of tick-borne encephalitis virus after vaccination with a new tick-borne encephalitis vaccine, 210
Knapp, B. *see* Schorr, J., 675
Kniskern, P. *see* Miskovsky, E., 346
Knorr, R. *see* Etlinger, H.M., 512
Koprowski, H. *see* Tollis, M., 134
Kotlarski, I. *see* Alm, R.A., 588
Krah, D.L. *see* Provost, P.J., 111
Kreeftenberg, J.G. *see* Relyveld, E., 369
Křivanec, K. *see* Klockmann, U., 42, 210
Krohina, M.A. *see* Stanislavsky, E.S., 491
Küpper, H.A. *see* Schorr, J., 675
Kurata, T. *see* Gizurarson, S., 825
Kuroda, S., Fujisawa, Y., Iino, S., Akahane, Y. and Suzuki, H. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine), 163
Kusov, Y.Y., Elbert, L.B., Nelga, I.V., Grishina, G.K., Dunaevski, O.A., Kharin, N.V., Maslov, Y.N., Drozdov, S.G. and Balayan, M.S. Immunogenicity trial of inactivated hepatitis A virus in human volunteers, 540
Kuter, B.J. *see* Provost, P.J., 111
Kuter, B.J., Weibel, R.E., Guess, H.A., Matthews, H., Morton, D.H., Neff, B.J., Provost, P.J., Watson, B.A., Starr, S.E. and Plotkin, S.A. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies, 643
Kwasny, H. *see* Klockmann, U., 42

LaBrooy, J.T. *see* Forest, B.D., 515
Lacetera, N.G. *see* Tengerdy, R.P., 204
Lachi, B-E. *see* Grosfeld, H., 451
Lai, W.C., Bennett, M., Pakes, S.P. and Murphree, S.S. Potential subunit vaccine against *Mycoplasma pulmonis* purified by a protective monoclonal antibody, 177
Lampiasi, A.M. *see* Ajello, F., 502
Languet, B. *see* Taylor, J., 190
Larsson, M. *see* Sjolander, A., 443
Lashkevich, V.A. *see* Amosenko, F.A., 207
Lathe, R. *see* Hareuveni, M., 618

Leclerc, C. *see* Perrin, P. 549
Lee, J.O. *see* Anderson Jr, G.W., 710
Lee, S-D. *see* Chan, C-Y., 765
Lee, T-Y. *see* Lin, H-H., 457
Lehman, D. *see* Byars, N.E., 309
Leitner, M. *see* Grosfeld, H., 451
Leoncio, M.M. *see* Fishbein, D.B., 581
Levi, G.C., de Mendonca, J.S. and Granato, C. Hepatitis B virus infection in a successfully immunized patient, 216
Levin, J. *see* Šourek, J., 106
Levine, M.M. *see* Hone, D.M., 810
Li Volti, S. *see* Giammanco, G., 747
Lifely, M.R., Roberts, S.C., Shepherd, W.M., Esdaile, J., Wang, Z., Cleverly, A., Aulaqi, A.A. and Moreno, C. Immunogenicity in adult males of a *Neisseria meningitidis* group B vaccine composed of polysaccharide complexed with outer membrane proteins, 60
Limbach, K. *see* Portetelle, D., 194
Lin, H-H., Chang, M-H., Chen, D-S., Sung, J-L., Hong, K-H., Young, Y-C., Yang, K-H. and Lee, T. Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysis of prophylaxis failure, 457
Lin, W. *see* Gönczöl, E., 631
Lindberg, A.A. *see* Verma, N.K., 6
Linde, K., Abraham, A.A. and Beer, J. Stable *Listeria monocytogenes* live vaccine candidate strains with graded attenuation on the mouse model, 101
Ling, C. *see* Page, M., 47
Little, S.P. *see* Kit, M., 564
Lo, K-J. *see* Chan, C-Y., 765
Lockey, R.F. *see* Russell, D.W., 691
London, W.T. *see* Treanor, J.J., 495
Looareesuwan, S. *see* Chongsa-nguan, M., 53
Lövgren, K. *see* Øvernes, G., 25
Lövgren, K. *see* Sjölander, A., 443
Lowe, C.U. *see* Siber, G.R., 735
Lubeck, M.D. *see* Chengalvala, M., 485
Lukacs, L.J. *see* Ahonkhai, V.I., S38
Lumlertdaecha, B. *see* Tepsumethanon, W., 627
Lustig, S. *see* Grosfeld, H., 451

Macdonald, L. *see* Poskitt, D.C., 792
Mackensie, N. *see* Jones, P.W., 29
Macreadie, I.G. *see* Azad, A.A., 715
Maggio, M. *see* Chiarini, A., 837
Makarenko, T.A. *see* Stanislavsky, E.S., 491
Mäkelä, P.H. *see* Kantele, A., 423, 428
Makoff, A.J. *see* Romanos, M.A., 901
Maluf Jr, P.T. *see* Cristófani, L.M., 873
Mammerickx, M. *see* Portetelle, D., 194
Mangahas, L.C. *see* Fishbein, D.B.. 581
Mangiafico, J.A. *see* Anderson Jr, G.W., 710
Manivel, V. and Rao, K.V.S. Interleukin-1 derived synthetic peptide as an added co-adjuvant in vaccine formulations, 395
Manning, P.A. *see* Alm, R.A., 588
Meadors, G. *see* Anderson Jr., G.W., 710
Meitin, C.A., Bender, B.S. and Small Jr, P.A. Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine, 751
Meltzer, M. *see* Fishbein, D.B., 581
de Mendonca, J.S. *see* Levi, G.C., 216
Mento, S.J. *see* Mishkin, E.M., 147
Mercado, D. *see* Fishbein, D.B., 581
Merrill, P. *see* Fishbein, D.B., 581
Meyer, H.L. *see* Ambrose, M.W., 505
Miller, T.J. *see* Wunderli, P.S., 638
Miller, W. *see* Miskovsky, E., 346
Miller, W.J. *see* Provost, P.J., 111
Mills, K.H.G. *see* Page, M., 47
Marciani, D.J., Kensil, C.R., Beltz, G.A., Hung, C., Cronier, J. and Aubert, A. Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats, 89
Margolis, H.S. *see* Coleman, P.J., 723
Markowitz, L.E. *see* Chen, R.T., 297
Marsili, I. *see* Podda, A., 741
Masia, M.D. *see* Chiarini, A., 837
Maslov, Y.N. *see* Kusov, Y.Y., 540
Mathieu, D. *see* Fattal-German, M., 542
Matsuda, T. *see* Kameoka, J., 605
Matthews, H. *see* Kuter, B.J., 643
Mauro, L. *see* Giammanco, G., 747
Mayrhofer, G. *see* Alm, R.A., 588
McChesney, D.G. *see* Boslego, J.W., 154
McComb, C. *see* Cooper, P.D., 408
McDougall, L. *see* Bielefeldt Ohmann, H., 170
McGee, J.P. *see* O'Hagan, D.T., 768
McKern, N.M. *see* Azad, A.A., 715
McKnight, A. *see* Page, M., 47
Mimms, L. *see* Hammond, G., 97
Minuk, G. *see* Hammond, G., 97
Miranda, N.J. *see* Fishbein, D.B., 581
Mishkin, E.M., Fahey, J.R., Kino, Y., Klein, R.J., Abramovitz, A.S. and Mento, S.J. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models, 147
Miskovsky, E., Gershman, K., Clements, M.L., Cupps, T., Calandra, G., Hesley, T., Ioli, V., Ellis, R., Kniskern, P., Miller, W., Gerety, R. and West, D. Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens, 346
Misra, C.N. *see* Gupta, R.K., 865
Mitchell, G.H. Editorial: Malaria research: has a useful malaria vaccine arrived?, 219
Mizutani, S. *see* Chengalvala, M., 485
Molli, I. *see* Blancou, J., 432
Molnar-Kimber, K. *see* Chengalvala, M., 485
Moonsammy, G.I. *see* Bush, L., 807
Mopri, T. *see* Kameoka, J., 605
Morein, B. *see* Sjölander, A., 443
Moreno, C. *see* Lifely, M.R., 60
Morin, J. *see* Chengalvala, M., 485
Morrill, J.C., Carpenter, L., Taylor, D., Ramsburg, H.H., Quance, J. and Peters, C.J. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep, 35
Morton, D.H. *see* Provost, P.J., 111
Morton, D.H. *see* Kuter, B.J., 643
Moses, J.M. *see* Chen, R.T., 297
Moxon, E.R. Supplement: Proceedings of the International Conference on Prevention of Hib Meningitis in the 1990s. Introduction, S4
Moxon, E.R. Supplement: Proceedings on the International Conference on Prevention of Hib Meningitis in the 1990s: Conclusion, S44
Mufson, M.A., Hughey, D.F., Turner, C.E. and Schiffman, G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination, 403
Mukherjee, R. *see* Singh, I.G., 10
Mulcahy, G., Pullen, L.A., Gale, C., DiMarchi, R.D. and Doel, T.R. Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines, 19
Müller, H-M. *see* von Brunn, A., 477
Murakami, Y. *see* Tsuda, T., 648
Murphree, S.S. *see* Lai, W.C., 177
Murphy, B.R. *see* Treanor, J.J., 495
Murphy, B.R. *see* Hall, S.L., 659
Murphy, B.R., Prince, G.A., Collins, P.L., Hildreth, S.W. and Paradiso, P.R. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV), 185
Musumeci, S. *see* Giammanco, G., 747

Naeve, C.W. *see* Henrickson, K.J., 243
Nakano, G. *see* Byars, N.E., 309
Neff, B.J. *see* Kuter, B.J., 643
Nelga, I.V. *see* Kusov, Y.Y., 540
Nencioni, L. *see* Podda, A., 741
Neri, M. *see* Zei, T., 613
Nesse, L.L. *see* Øvernes, G., 25
Neto, V.A. *see* Cristófani, L.M., 873
Noel, A. *see* Ruuskanen, O., 117
Noskov, E.S. *see* Budowsky, E.I., 398
Nygren, P-Å. *see* Sjölander, A., 443

O'Hagan, D.T., Jeffery, H., Roberts, M.J.J., McGee, J.P. and Davis, S.S. Controlled release microparticles for vaccine development, 768
Oato, N.H. *see* Relyveld, E., 843
Odone-Filho, U. *see* Cristófani, L.M., 873
Ogawa, H. *see* Gizurarson, S., 825
Ohgitani, T., Okabe, T. and Sasaki, N. Characterization of haemagglutinin from *Bordetella bronchiseptica*, 653
Okabe, T. *see* Ohgitani, T., 653
Olivier-Bernardin, V. *see* Jacques, I., 896
Olsen, M. *see* Hunter, R., 250
Olsen, M. *see* Takayama, K., 257
Orenstein, W.A. *see* Chen, R.T., 297
Oselka, G.W. *see* Cristófani, L.M., 873
Overnes, G., Nesse, L.L., Waldeland, H., Lövgren, K. and Gudding, R. Immune response after immunization with an experimental *Toxoplasma gondii* ISCOM vaccine, 25

Page, M., Mills, K.H.G., Schild, G.C., Ling, C., Patel, V., McKnight, A., Barnard, A.L., Dilger, P. and Thorpe, R. Studies on the immunogenicity of chinese hamster ovary cell-derived recombinant gp120 (HIV-1_{IIIB}), 47
Pakes, S.P. *see* Lai, W.C., 177
Palma, R. *see* Dentico, P., 438
Pannuti, C. *see* Cristófani, L.M., 873
Paoletti, E. *see* Taylor, J., 190
Paoletti, E. *see* Portetelle, D., 194
Paoletti, E. *see* Webster, R.G., 303
Paoletti, E. *see* Gönczöl, E., 631
Paradiso, P.R. *see* Murphy, B.R., 185
Paradiso, P.R., Hu, B.T., Arumugham, R. and Hildreth, S. Mapping of a fusion related epitope of the respiratory syncytial virus fusion protein, 231
Parker, J. *see* Hammond, G., 97
Parr, E.L. *see* Thapar, M.A., 129
Parr, M.B. *see* Thapar, M.A., 129
Parry, N.R. *see* Brown, A.L., 595
Pastore, G. *see* Dentico, P., 438
Patel, V. *see* Page, M., 47
Peixoto, V. *see* Cristófani, L.M., 873
Peltola, H. *see* Eskola, J., S14
Peppoloni, S. *see* Podda, A., 741
Perrin, P., Joffret, M-L., Zanetti, C., Bourhy, H., Gontier, C., Fritzell, C., Leclerc, C. and Sureau, P. Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees, 549
Peters, C.J. *see* Morrill, J.C., 35
Pêtre, J. *see* Ruuskanen, O., 117
Petruccelli, B.P. *see* Ronish, R.H., 364
Phanuphak, P. *see* Tepsumethanon, W., 627
Phillpotts, R.J. *see* Erturk, M., 668, 728
Piatti, P. *see* Berinstein, A., 883
Piziak, M.V. *see* Boslego, J.W., 154
Plotkin, S. *see* Gönczöl, E., 631
Plotkin, S.A. *see* Kuter, B.J., 643
Podda, A., Nencioni, L., Marsili, I., Peppoloni, S., Volpini, G., Donati, D., Di Tommaso, A., De Magistris, M.R. and Rappuoli, R. Phase 1 clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa, 741
Polsuwan, C. *see* Tepsumethanon, W., 627
Popova, V.D. *see* Amosenko, F.A., 207
Portetelle, D., Limbach, K., Burny, A., Mammerickx, M., Desmettre, P., Riviere, M., Zavada, J. and Paoletti, E. Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection, 194
Portner, A. *see* Henrickson, K.J., 243
Poskitt, D.C., Jean-Francois, M.J.B., Turnbull, S., Macdonald, L. and Yasmeen, D. Internal image (Ab2β) anti-idiotype vaccines. Theoretical and practical aspects, 792
Potter, A. *see* Bielefeldt Ohmann, H., 170
Potter, C.W. *see* Erturk, M., 668
Powell, N. *see* Anderson Jr, G.W., 710
Praus, M. *see* Klockmann, U., 42
Presti, A. *see* Ghirga, G., 913
Prince, G.A. *see* Murphy, B.R., 185
Provost, P.J. *see* Kuter, B.J., 643
Provost, P.J., Krah, D.L., Kuter, B.J., Morton, D.H., Schofield, T.L., Wasmuth, E.H., White, C.J., Miller, W.J. and Ellis, R.W. Antibody assays suitable for assessing immune responses to live varicella vaccine, 111
Pullen, L.A. *see* Mulcahy, G., 19
Putto-Laurila, A. *see* Ruuskanen, O., 117

Quance, J. *see* Morrill, J.C., 35
Quast, U., Herder, C. and Zwisler, O. Vaccination of patients with Encephalomyelitis disseminata, 228
Quast, U. *see* Fescharek, R., 868
Quirie, M. *see* Gilmour, N.J.L., 137

Ramadass, P. *see* Jayakumar, R., 611
Ramsburg, H.H. *see* Morrill, J.C., 35
Rao, K.V.S. *see* Manivel, V., 395
Rappuoli, R. *see* Podda, A., 741
Relyveld, E., Oato, N.H., Guerin, N., Coursaget, P., Huet, M. and Gupta, R.K. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal, 843
Relyveld, E., Bengounia, A., Huet, M. and Kreeftenberg, J.G. Antibody response of pregnant women to two different adsorbed tetanus toxoids, 369
Relyveld, E.H. *see* Gupta, R.K., 699
Resti, M., Azzari, C., Rossi, M.E., Adami Lami, C., Tucci, F. and Vierucci, A. Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses, 15
Riemann, H. *see* Tengerdy, R.P., 273
Rigo, G. *see* Chiarini, A., 837
Riviere, M. *see* Portetelle, D., 194
Roberts, M.J.J. *see* O'Hagan, D.T., 768
Roberts, S.C. *see* Lifely, M.R., 60
Robinson, A. *see* Abraham, E., 757
Rochat, H. *see* Chavez-Olortegui, C., 907
Rodinò, P. *see* Ghirga, G., 913
Romanos, M.A., Clare, J.J., Beesley, K.M., Rayment, F.B., Ballantine, S.P., Makoff, A.J., Dougan, G., Fairweather, N.F. and Charles, I.G. Recombinant *Bordetella pertussis* pertactin (P69) from the yeast *Pichia pastoris*: high-level production and immunological properties, 901
Ronish, R.H., Diniega, B.M., Kelley, P.W., Sjögren, M.H., Arday, D.R., Aronson, N.E., Hoke, C.H. and Petruccelli, B. Immunogenicity achieved by the intradermal hepatitis B vaccination programme for US Army soldiers in Korea, 364
Rossi, M.E. *see* Resti, M., 15
Rowlands, D.J. *see* Brown, A.L., 595
Ruangkunaporn, Y. *see* Chongsa-nguan, M., 53
Rusanov, V.M. *see* Stanislavsky, E.S., 491
Russell, D.W., Cameron, D.J., Lockey, R.F., Behnke, R.H., Sinnott, J.T. and Ganguly, R. Influenza vaccination acceptance among health care professionals, 691
Ruuskanen, O., Noel, A., Putto-Laurila, A., Pêtre, J., Capiau, C., Delem, A., Vandevoorde, D., Simoen, E., Teuwen, D.E., Bogaerts, H. and André, F.E. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults, 117

Sadir, A.M. *see* Berinstein, A., 883
Sadoff, J.C. *see* Boslego, J.W., 154
Saint-Cyr, A. *see* Teulieres, L., 521
Salemi, I. *see* Giammanco, G., 747
Saliou, P. *see* Teulieres, L., 521
Saliou, P. *see* Soulié, J.C., 545
Salva, E. *see* Fishbein, D.B., 581
Sansonetti, P.J., Arondel, J., Fontaine, A., d'Hauteville, H. and Bernardini, M.L. *OmpB* (osmo-regulation) and *icsA* (cell-to-cell spread) mutants of *Shigella flexneri*: vaccine candidates and probes to study the pathogenesis of shigellosis, 416
Santarelli, J. *see* Soulié, J.C., 545
Sarzana, A. *see* Chiarini, A., 837
Sasaki, N. *see* Ohgitani, T., 653
Saxena, S.N. *see* Gupta, R.K., 215, 865
Scarpa, B. *see* Chiarini, A., 837
Schalm, S.W. *see* Grosheide, P.M., 682
Schiffman, G. *see* Mufson, M.A., 403
Schild, G.C. *see* Page, M., 47
Schiraldi, O. *see* Dentico, P., 438
Schofield, T.L. *see* Provost, P.J., 111
Schorr, J., Knapp, B., Hundt, E., Küpper, H.A. and Amann, E. Surface expression of malarial antigens in *Salmonella typhimurium*: induction of serum antibody response upon oral vaccination of mice, 675
Schudel, A.A. *see* Berinstein, A., 883
Schwarz, S. *see* Fescharek, R., 868
Scott Schmid, D. *see* Wunderli, P.S., 638
Seeber, S.J., White, J.L. and Hem, S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants, 201
Sekla, L. *see* Hammond, G., 97
Sekura, R.D. *see* Siber, G.R., 735
Sergienko, A.I. *see* Stanislavsky, E.S., 491
Serovich, J. *see* Coleman, P.J., 723
Shaddock, J.H. *see* Wunderli, P.S., 638
Shafferman, A. *see* Grosfeld, H., 451
Sharm, S.B. *see* Gupta, R.K., 215
Sharma, B. *see* Sokhey, J., 69
Sharma, Y.D. *see* Biswas, S., 467
Shaw Jr., F.E. *see* Coleman, P.J., 723
Shepherd, W.M. *see* Lifely, M.R., 60
Shiobara, S. *see* Kameoka, J., 605
Siber, G.R., Thakrar, N., Yancey, B.A., Herzog, L., Todd, C., Cohen, N., Sekura, R.D. and Lowe, C.U. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid

in 18-month-old children, 735
Simoen, E. *see* Ruuskanen, O., 117
Singh, I.G., Mukherjee, R. and Talwar, G.P. Resistance to intravenous inoculation of *Mycobacterium tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w*, 10
Sinnott, J.T. *see* Russell, D.W., 691
Sjögren, M.H. *see* Ronish, R.H., 364
Sjölander, A., Lövgren, K., Ståhl, S., Åslund, L., Hansson, M., Nygren, P-Å., Larsson, M., Hagstedt, M., Wåhlin, B., Berzins, K., Uhlén, M., Morein, B. and Perlmann, P. High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the *Plasmodium falciparum* antigen Pf155/RESA, 443
Slater, P.E. Poliomyelitis vaccination: the essential booster, 527
Small Jr, P.A. *see* Meitin, C.A., 751
Sokhey, J., Gupta, C.K., Sharma, B. and Gupta, R.K. Statistical analysis of virus titres obtained in repeated assays of working standard of trivalent oral polio vaccine, 69
Sopungco, P.V. *see* Fishbein, D.B., 581
Sordelli, D.O. *see* Hooke, A.M., 294
Soria Baltazar, R. *see* Blancou, J., 432
Soulié, J.C., Devillier, P., Santarelli, J., Goudeau, A., Vermeulen, P., Guellier, M., Saliou, P., Hillion, A.M., Tron, F. and Huchet, J. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens, 545
Šourek, J., Levin, J., Trnka, T. and Zelenková, L. New trends in the use of $Al(OH)_3$-conjugated endotoxins and their subunits from the S- and R-forms of *Shigella dysenteriae* serovar 1 for model vaccination purposes, 106
Souza Marques, H.H. *see* Cristófani, L.M., 873
Spier, R.E. Editorial: Vaccine goes monthly, 3
Spier, R.E. There are viruses and *viruses* . . ., 861
Ståhl, S. *see* Sjölander, A., 443
Stanislavsky, E.S., Balayan, S.S., Sergienko, A.I., Makarenko, T.A., Edvabnaya, L.S., Krohina, M.A. and Rusanov, V.M. Clinico-immunological trials of *Pseudomonas aeruginosa* vaccine, 491
Starr, S.E. *see* Kuter, B.J., 643
Staub, J.M. *see* Vella, P.P., S26
Steele, E.J. *see* Cooper, P.D., 351, 408
Stephenson, J.R. *see* Klockmann, U., 210
Stoltz, J.F. *see* Blancou, J., 432
Stroffolini, T. *see* Chiarini, A., 837
Sugimura, T. *see* Tsuda, T., 648
Sundquist, B. *see* Carlsson, U., 577
Sung, J-L. *see* Lin, H-H., 457
Sureau, P. *see* Perrin, P., 549
Sutherland, A.D. *see* Gilmour, N.J.L., 137
Suzuki, H. *see* Kuroda, S., 163
Svitkin, Y.V. *see* Amosenko, F.A., 207
Taillandier, J. *see* Fattal-German, M., 542
de Taisne, C. *see* Gönczöl, E., 631
Takala, A. *see* Eskola, J., S14
Takayama, K., Olsen, M., Datta, P. and Hunter, R.L. Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors, 257
Takegawa, M. *see* Kataoka, T., 300
Talwar, G.P. *see* Singh, I.G., 10
Tamura, S. *see* Gizurarson, S., 825
Taormina, S. *see* Chiarini, A., 837
Tate, R. *see* Hammond, G., 97
Taylor, D. *see* Morrill, J.C., 35
Taylor, J. *see* Webster, R.G., 303
Taylor, J., Trimarchi, C., Weinberg, R., Languet, B., Guillemin, F., Desmettre, P. and Paoletti, E. Efficacy studies on a canarypox-rabies recombinant virus, 190
Tengerdy, R.P. and Lacetera, N.G. Vitamin E adjuvant formulations in mice, 204
Tengerdy, R.P., Ameghino, E. and Riemann, H. Serological responses of rams to a *Brucella ovis*–vitamin E adjuvant vaccine, 273
Tepsumethanon, W., Polsuwan, C., Lumlertdaecha, B., Khawplod, P., Hemachudha, T., Chutivongse, S., Wilde, H., Chiewbamrungkiat, M. and Phanuphak, P. Immune response to rabies vaccine in Thai dogs: A preliminary report, 627
Terletskaya, E.N. *see* Amosenko, F.A., 207
Teulieres, L., Diouf, M.A., Chaud, P., Saint-Cyr, A. and Saliou, P. Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana, 521
Teuwen, D.E. *see* Ruuskanen, O., 117
Thakrar, N. *see* Siber, G.R., 735
Thapar, M.A., Parr, E.L., Bozzola, J. and Parr, M.B. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM), 129
Thompson, W. *see* Ansher, S., 277
Thorpe, R. *see* Page, M., 47
Tierney, E.L. *see* Treanor, J.J., 495
Timofeev, A.V. *see* Amosenko, F.A., 207
Todd, C. *see* Siber, G.R., 735
Tokunaga, T. *see* Kataoka, T., 300
Tollis, M., Dietzschold, B., Volia, C.B. and Koprowski, H. Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies, 134
Tomasetto, C. *see* Hareuveni, M., 618
Tomkova, E. *see* Klockmann, U., 42
Tomley, F.M. Recombinant vaccines for poultry, 4
Tramont, E.C. *see* Boslego, J.W., 154
Treanor, J.J., Tierney, E.L., London, W.T. and Murphy, B.R. Characterization of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during *in vitro* production of avian–human reassortant vaccine viruses and after replication in humans and primates, 495
Trimarchi, C. *see* Taylor, J., 190
Trivello, R. *see* Chiarini, A., 837
Trnka, T. *see* Šourek, J., 106
Tron, F. *see* Soulié, J.C., 545
Tsai, Y-T. *see* Chan, C-Y., 765
Tsuda, T., Sugimura, T. and Murakami, Y. Evaluation of glycoprotein gII ISCOMs subunit vaccine for pseudorabies in pig, 648
Tucci, F. *see* Resti, M., 15
Turnbull, P.C.B. Anthrax vaccines: past, present and future, 533
Turnbull, S. *see* Poskitt, D.C., 792
Turner, C.E. *see* Mufson, M.A., 403

Uhlén, M. *see* Sjölander, A., 443

Vandevoorde, D. *see* Ruuskanen, O., 117
van Osand, H.C. *see* Grossheide, P.M., 682
van Wyke Coelingh, K.L. *see* Henrickson, K.J., 243
van Wyke Coelingh, K.L. *see* Hall, S.L., 659
Varis, T. *see* Vesikari, T., 334
Velan, B. *see* Grosfeld, H. 451
Vella, P.P., Staub, J.M. and Ellis, R.W. Biological activity of Hib conjugates, S26
Venkatesan, M., Fernandez-Prada, C., Buysse, J.M., Formal, S.B. and Hale, T.L. Virulence phenotype and genetic characteristics of the T32-ISRATI *Shigella flexneri* 2a vaccine strain, 358
Verma, N.K. and Lindberg, A.A. Construction of aromatic dependent *Shigella flexneri* 2a live vaccine candidate strains: deletion mutations in the *aro*A and the *aro*D genes, 6
Vermeulen, P. *see* Soulié, J.C., 545
Vesikari, T., Varis, T., Green, K., Flores, J. and Kapikian, A.Z. Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity, 334
Vierucci, A. *see* Resti, M., 15
Villas Boas, L.S. *see* Cristófani, L.M., 873
Volia, C.B. *see* Tollis, M., 134
Volpe, A. *see* Dentico, P., 438
Volpini, G. *see* Podda, A., 741
von Brunn, A., Früh, K., Müller, H.-M., Zentgraf, H.-W. and Bujard, H. Epitopes of human malaria parasite *P. falciparum* carried on the surface of the HBsAg particles elicit an immune response against the parasite, 477
Vreeswijk, J. *see* Barteling, S.J., 75

Wahlin, B. *see* Sjölander, A., 443
Waldeland, H. *see* Øvernes, G., 25
Walker, P.D. Supplement: Proceedings of the International Conference on

Prevention of Hib Meningitis in the 1990s. Editorial, S3
Wan, K.S. *see* Hooke, A.M., 294
Wang, Z. *see* Lifely, M.R., 60
Wang, Z. *see* Hooke, A.M., 238, 294
Ward, C.W. *see* Azad, A.A., 715
Ward, J. Prevention of invasive Haemophilus influenzae type b disease: lessons from vaccine efficacy trials, S17
Wasmuth, E.H. *see* Provost, P.J., 111
Wathen, M.W. *see* Brideau, R.J., 863
Watson, B.A. *see* Kuter, B.J., 643
Webster, R.G., Kawaoka, Y., Taylor, J., Weinberg, R. and Paoletti, E. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens, 303
Weibel, R.E. *see* Kuter, B.J., 643
Weinberg, A. *see* Cristófani, L.M., 873
Weinberg, R. *see* Taylor, J., 190
Weinberg, R. *see* Webster, R.G., 303
Welch, M. *see* Byars, N.E., 309
Welch, M.J. *see* Erturk, M., 728
West, D. *see* Miskovsky, E., 346
White, C.J. *see* Provost, P.J., 111
White, J.L. *see* Seeber, S.J., 201
Wilde, H. *see* Chutivongse, S., 573
Wilde, H. *see* Tepsumethanon, W., 627
Winkler, W.G. *see* Fishbein, D.B., 581
Wood, S.W. *see* Boslego, J.W., 154
Wreschner, D.H. *see* Hareuveni, M., 618
Wunderli, P.S., Shaddock, J.H., Scott Schmid, D., Miller, T.J. and Baer, G.M. The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines, 638
Wyde, P.R. *see* Ambrose, M.W., 505

Yancey, B.A. *see* Siber, G.R., 735
Yang, K-H. *see* Lin, H-H., 457
Yarosh, W. *see* Brown, E.G., 840
Yasmeen, D. *see* Poskitt, D.C., 792
Yoshinaga, K. *see* Kameoka, J., 605
Young, Y-C. *see* Lin, H-H., 457

Zalesskaya, M.A. *see* Budowsky, E.I., 319
Zanetti, C. *see* Perrin, P., 549
Zavada, J. *see* Portetelle, D., 194
Zavoianni, A. *see* Dentico, P., 438
Zei, T., Neri, M. and Iorio, A.M. Immunogenicity of trivalent subunit and split influenza vaccines (1989–90 winter season) in volunteers of different groups of age, 613
Zelenkova, L. *see* Šourek, J., 106
Zentgraf, H-W. *see* von Brunn, A., 477
Zheleznova, N.V. *see* Budowsky, E.I., 398, 473
Zwisler, O. *see* Quast, U., 228

Subject Index

AIDS research: *see* SIV vaccines, 787
AIDS vaccine: Final report of the Keystone AIDS vaccine liability project, 703
Abbreviated rabies vaccine schedules: One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine, 573
Acellular vaccine: Phase 1 clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa, 741
Acellular vaccine: *see* Pertussis, 117
Adenovirus: Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs, 485
Adjuvant: Induction of immune response to protein antigens by subcutaneous co-injection with water-miscible vitamin A derivatives, 122
Adjuvant: *see* Block copolymer, 250
Adjuvant: *see* Copolymer, 257
Adjuvant: *see* Hepatitis vaccine, 309
Adjuvant: *see* Inulin, 351, 408
Adjuvants: Serological responses of rams to a *Brucella ovis*–vitamin E adjuvant vaccine, 273
Adjuvants: Vitamin E adjuvant formulations in mice, 204
Adolescents: *see* Diphtheria antitoxin titres, 502
Adverse effects: *see* Measles–mumps–rubella vaccine, 297
Adverse reactions: *see* Tetanus and diphtheria toxoids, 699
Aerosol: *see* Rift Valley fever virus, 710
Age: *see* Influenza vaccines, 613
Alum: *see* Inulin, 408
Aluminium hydroxyphosphate: Predicting the adsorption of proteins by aluminium-containing adjuvants, 201
Anthrax vaccines: Anthrax vaccines: past, present and future, 533
Anti-idiotypes: *see* Idiotypes, 792
Anti-pre-S2 antibodies: Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine), 163
Anti-tumour immunity: Effect of a synthetic adjuvant for inducing anti-tumour immunity, 300
Antibodies: *see* Syphilis, 266
Antibodies: *see* *Plasmodium falciparum*, 467
Antibody assays: Antibody assays suitable for assessing immune responses to live varicella vaccine, 111
Antibody persistence: Hepatitis B virus infection in hospital staff: epidemiology and persistence of vaccine-induced antibodies, 438
Antibody-mediated immune suppression: Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV), 185
Antibody: *see* Recombinant vaccinia virus, 470
Antigen presentation: Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted, 595
Aro genes: Oral vaccination of calves against experimental salmonellosis using a double *aro* mutant of *Salmonella typhimurium*, 29
Attenuation: *see* T32-ISTRATI, 358

B. bronchiseptica: *see* Haemagglutinin, 653
B subunit of cholera toxin: *see* Cholera toxin, 825
B-cell response: *see* T–B cell interactions, 170
BCG: Comparative trial of administration of half (0.05 mg) and quarter (0.025 mg) dose of intradermal Pasteur BCG on 291 infants from birth to 1 year in French Guyana, 521
Bacteriophage MS2: *see* Kinetics of inactivation, 319
Baculovirus vector: *see* PIV3 fusion glycoprotein, 659
Beta propiolactone: Principles of selective inactivation of viral genome. VII. Some peculiarities in determination of viral suspension infectivity during inactivation by chemical agents, 473
Biodegradable microparticles: Controlled release microparticles for vaccine development, 768
Block copolymer: Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody, 250
Book Reviews: 143, 375, 692, 854, 915

Booster response: Booster response to recombinant yeast-derived hepatitis B in vaccinees whose anti-HBs responses were initially elicited by a plasma-derived vaccine, 765
Bovine herpesvirus: *see* Recombinant, 564
Bovine leukaemia virus: *see* Recombinant vaccinia virus, 194
Bovine leukaemia virus: *see* Cell-derived vaccines, 889
Bovine virus diarrhoea virus: *see* ISCOMs, 577
Breast cancer: Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA), 618

Calves: *see Aro* genes, 29
Cancer in children: *see* Varicella, 873
Canarypox: *see* Recombinant, 190
Cell-derived vaccines: Protective vaccination against bovine leukaemia virus infection by means of cell-derived vaccine, 889
Cellular immunity: Enhancement of the immune response elicited with foot-and-mouth disease virus vaccines by an extract of the *Mycobacterium* sp. wall, 883
Chimpanzee: *see* Anti-pre-S2 antibodies, 163
Cholera toxin: The effect of cholera toxin and cholera toxin B subunit on the nasal mucosal membrane, 825
Circulating antibodies: *see* Tetanus toxoid, 369
Clinical experience: *see Haemophilus influenzae* conjugate, 38
Clinical trials: *see Pseudomonas aeruginosa*, 491
Co-adjuvant: Interleukin-1 derived synthetic peptide as an added co-adjuvant in vaccine formulations, 395
Component pertussis vaccine: *see* Whole cell pertussis vaccine, 843
Conference Report, 286, 463, 693, 914
Conjugate: *see Escherichia hermannii*, 559
Conjugate vaccine: *see Haemophilus influenzae* type b, 14, 26, 30
Copolymer: Adjuvant activity of nonionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors, 257
Cost–benefit analysis: *see* Rabies vaccine, 581

Diphtheria: Immunity to diphtheria in the 3–19 year age group in Italy, 837
Diphtheria antitoxin titres: Circulating diphtheria antitoxin levels in children aged 11–14 years in relation to the vaccinal history, 502
Drug metabolism: Vaccine-induced alterations in hepatic drug metabolism, 277

Elderly: *see* Revaccination, 403
Elderly: *see* Pneumonia, 542
Encephalomyelitis disseminata: Vaccination of patients with Encephalomyelitis disseminata, 228
Envelope glycoprotein: *see* Semliki Forest virus, 451
Envelope proteins: Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens, 346
Epidemiology: *see Haemophilus influenzae*, 5, 10
Epithelial tumour antigen: *see* Breast cancer, 618
Escherichia hermannii: *Escherichia hermannii* (ATCC 33651) polysaccharide–protein conjugates: comparison of two conjugation methods for the induction of humoral responses in mice, 559

Feline leukaemia virus: Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats, 89
Field trials: *see* Hib vaccine, 17
Foot-and-mouth disease: Mouse protection test as a predictor of the protective capacity of synthetic foot-and-mouth disease vaccines, 19
Foot-and-mouth disease: *see* Safety of vaccines, 75
Foot-and-mouth disease: *see* Cellular immunity, 883
Fowlpox virus: *see* Recombinants, 303
Fusion epitope: Mapping of a fusion related epitope of the respiratory syncytial virus fusion protein, 231
Fusion protein: *see* Fusion epitope, 231

Genetic reassortants: Immunogenicity and safety of rhesus–human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity, 334
Genetic reassortment: Characterization of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during *in vitro* production of avian–human reassortant vaccine viruses and after replication in humans and primates, 495
Glycoprotein D: Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models, 147
Glycoprotein: Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats, 505
Graded attenuation: Stable *Listeria monocytogenes* live vaccine candidate strains with graded attenuation on the mouse model, 101

HBsAg-gp190 hybrids: Epitopes of the human malaria parasite *P. falciparum* carried on the surface of HBsAg particles elicit an immune response against the parasite, 477
HCMV: High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity, 631
HIV infection: The quest for vaccines against AIDS – progress and challenges, 779
HIV vaccines: Are we detouring from a direct route to development of HIV vaccines?, 783
HIV vaccines: The challenge of HIV vaccines, 781
HIV: *see* Recombinant gp120, 47
HSV-1 ISCOM vaccine: Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection, 728
HSV-1 glycoproteins: *see* ISCOMs, 668
Haemagglutinin: Characterization of haemagglutinin from *Bordetella bronchiseptica*, 653
Haemagglutinin: *see* T cell response, 340
Haemolysin: *see Vibrio cholerae*, 588
Haemophilus influenzae: Epidemiology of *Haemophilus influenzae* type b disease in Australia and New Zealand, 10
Haemophilus influenzae: World-wide epidemiology of *Haemophilus influenzae* meningitis; industrialized versus non-industrialized countries, 5
Haemophilus influenzae conjugate: Clinical experience with PedvaxHIB, a conjugate vaccine of *Haemophilus influenzae* type b polysaccharide–*Neisseria meningitidis* outer membrane protein, 38
Haemophilus influenzae type b: Biological activity of Hib conjugates, 26
Haemophilus influenzae type b: Comparative immunogenicity of *Haemophilus influenzae* type b polysaccharide–protein conjugate vaccines, 30
Haemophilus influenzae type b: Experience in Finland with *Haemophilus influenzae* type b vaccines, 14
Hepatitis A: Immunogenicity trial of inactivated hepatitis A virus in human volunteers, 540
Hepatitis B core particles: *see* Antigen presentation, 595
Hepatitis B vaccine: Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines, 97
Hepatitis B vaccine: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another, 807
Hepatitis B virus: *see* Perinatal transmission, 457
Hepatitis B: Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy, 747
Hepatitis B: Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens, 545
Hepatitis B: Immunoprophylaxis to limit a hepatitis B epidemic among women undergoing *in vitro* fertilization, 682
Hepatitis B: *see* Newborn vaccination, 15

Hepatitis B: *see* Envelope proteins, 346
Hepatitis B: *see* Intradermal vaccination, 364
Hepatitis B: *see* Antibody persistence, 438
Hepatitis vaccine: Improvement of hepatitis B vaccine by the use of a new adjuvant, 309
Herpes simplex virus: *see* Glycoprotein D, 147
Hib vaccine: Prevention of invasive *Haemophilus influenzae* type b disease: lessons from vaccine efficacy trials, 17
Hib-conjugate vaccines: Strategies for immunization against invasive *Haemophilus influence* type b infection, 35
Host–parasite: Review – Immunoparasitological parameters in schistosomiasis – A perspective view of a vaccine-oriented immunochemist, 379
Human: *see* Anti-pre-S2 antibodies, 163
Humoral immunity: Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization, 42
Humoral neutralizing antibody: The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines, 638
Hydrogen peroxide-inactivated: *see* Pertussis, 735

ISCOM: Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM), 129
ISCOMs: Biochemical characterization of herpes simplex virus type-1-immunostimulating complexes (ISCOMs): a multi-glycoprotein structure, 668
ISCOMs: Evaluation of glycoprotein gII ISCOMs subunit vaccine for pseudorabies in pig, 648
ISCOMs: High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the *Plasmodium falciparum* antigen Pf155/RESA, 443
ISCOMs: Immune response after immunization with an experimental *Toxoplasma gondii* ISCOM vaccine, 25
ISCOMs: Protective effect of an ISCOM bovine virus diarrhoea virus (BVDV) vaccine against an experimental BDV infection in vaccinated and non-vaccinated pregnant ewes, 577
Idiotypes: Internal image (Ab2Beta) anti-idiotype vaccines. Theoretical and practical aspects, 792
Immune response: *see* HBsAg-gp190 hybrids, 477
Immunity: *see* Ribonucleoprotein, 134
Immunization of children: *see* Whole cell pertussis vaccine, 843
Immunization strategies: *see* Hib-conjugate vaccines, 35
Immunization: *see* Influenza virus, 330
Immunogenicity: *see* Hepatitis B vaccine, 97
Inactivated: *see* Hepatitis A, 540
Inactivation kinetics: Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of β-propiolactone, 398
Inactivation: *see* β-propiolactone, 473
Infancy: *see* Hepatitis B, 747
Infants: *see* BCG, 521
Infectious bursal disease virus: *see* Recombinant antigen, 715
Influenza vaccines: Immunogenicity of trivalent subunit and split influenza vaccines (1989–90 winter season) in volunteers of different groups of age, 613
Influenza vaccines: *see* Genetic reassortment, 495
Influenza virus: Programmed antigenic stimulation: kinetics of the immune response to challenge infections of mice primed with influenza inactivated whole virus or neuraminidase vaccine, 330
Influenza: *see* Recombinants, 303
Influenza: *see* Inactivation kinetics, 398
Influenza: vaccinia: *see* Recombinant, 751
Inhibition of attachment: *see Neisseria gonorrhoeae* pili, 154
Interleukin-1: *see* Co-adjuvant, 395
Interleukin-2: Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees, 549
Intradermal: Intradermal hepatitis B vaccination in a large hospital employee population, 723
Intradermal vaccination: Immunogenicity achieved by the intradermal hepatitis B vaccination programme for US Army soldiers in Korea, 364
Inulin: Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and *in vitro* properties, 351
Inulin: The adjuvanticity of Algammulin, a new vaccine adjuvant, 408
Iron-regulated proteins: *see Pasteurella haemolytica*, 137

Japanese encephalitis vaccine: An efficient method for production of purified inactivated Japanese encephalitis vaccine from mouse brains, 865

Kinetics of inactivation: Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of β-propiolactone, 319

Leprosy vaccine: *see* Protective immunity, 10
Leprosy vaccines: Leprosy vaccines, 291
Lipid A: : *see Shigella dysenteriae* serovar 1 S- and R-form, 106
Liposomes: *In vivo* protection against scorpion toxins by liposomal immunization, 907
Listeria monocytogenes: *see* Graded attenuation, 101
Live vaccine: Construction of aromatic dependent *Shigella flexneri* 2a live vaccine candidate strains: deletion mutations in the *aro*A and the *aro*D genes, 6
Lyme disease: Perspective on the development of vaccines against Lyme disease, 531

Malaria vaccine: Editorial: Malaria research: has a useful malaria vaccine arrived?, 219
Malaria: *see* ISCOMs, 443
Malarial antigens: *see* Oral immunization, 675
Measles–mumps–rubella vaccine: Adverse events following measles–mumps–rubella and measles vaccinations in college students, 297
Meningitis: *see* Mumps, 840
Monoclonal antibodies: Detection of stable epitopes on formaldehyde-detoxified *Pasteurella multocida* toxin by monoclonal antibodies, 817
Monoclonal antibodies: *see* Mycoplasma pulmonis, 177
Mucosal immunity: Active immunity is seen as a reduction in the cell response to oral live vaccine, 428
Mucosal immunity: *see* ISCOM, 129
Mumps: Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients, 840
Mycoplasma pulmonis: Potential subunit vaccine against *Mycoplasma pulmonis* purified by a protective monoclonal antibody, 177

Neisseria gonorrhoeae pili: Efficacy trial of a parenteral gonococcal pilus vaccine in men, 154
Neisseria meningitidis: *see* Outer membrane protein, 60
Newborn vaccination: Five-year follow-up of vaccination against hepatitis B virus in newborns vaccinated with a reduced number of doses, 15
Newborn: *see* Hepatitis B, 545
NIH potency test: *see* Humoral neutralizing antibody, 638

O antigen: *In vivo* evidence of immunological masking of the *Vibrio cholerae* O-antigen of a hybrid *Salmonella typhi* Ty21a–*Vibrio cholerae* oral vaccine in humans, 515
O-polysaccharide–BSA conjugate, 896
Opsonization: Group A streptococcal antigens and vaccine potential, 797
Oral immunization: Oral immunization of mice with temperature-sensitive

Pseudomonas aeruginosa enhances pulmonary clearance of the wild-type, 294
Oral immunization: Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia, 757
Oral immunization: Oral immunization with *Salmonella typhi* Ty21a-based clones expressing *Vibrio cholerae* O-antigen: serum bactericidal antibody responses in man in relation to pre-immunization antibody levels, 877
Oral immunization: Surface expression of malarial antigens in *Salmonella typhimurium*: induction of serum antibody response upon oral vaccination of mice, 675
Outer membrane protein: Immunogenicity in adult males of a *Neisseria meningitidis* group B vaccine composed of polysaccharide complexed with outer membrane proteins, 60

PIV-3: *see* Synthetic peptides, 243
PIV3 fusion glycoprotein: Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus, 659
Parainfluenza: *see* Glycoprotein, 505
Pasteurella haemolytica: Vaccine containing iron-regulated proteins of *Pasteurella haemolytica* A2 enhances protection against experimental pasteurellosis in lambs, 137
Pasteurella multocida toxin: *see* Monoclonal antibodies, 817
Patent Report, 67, 141, 213, 284, 373, 461, 525, 602, 688, 772, 851, 911
Pathogenesis: *OmpB* (osmo-regulation) and *icsA* (cell-to-cell spread) mutants of *Shigella flexneri*: vaccine candidates and probes to study the pathogenesis of shigellosis, 416
Perinatal transmission: Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysis of prophylaxis failure, 457
Persistence of antibody: *see* Varicella vaccine, 643
Pertussis: Development of an acellular pertussis vaccine and its administration as a booster in healthy adults, 117
Pertussis: Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children, 735
Pertussis: *see* Acellular, 741
Pertussis vaccines: Recombinant *Bordetella pertussis* pertactin (P69) from the yeast *Pichia pastoris*: high-level production and immunological properties, 901
Plasmodium falciparum: Human response to a malaria vaccine candidate antigen, 467
Pneumococcal vaccine: *see* Revaccination, 403
Pneumonia: Pneumococcal vaccination of elderly individuals, 542
Pneumonia: *see* Oral immunization, 757
Poliomyelitis vaccine: Use of protamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines, 207
Polysaccharide: *see* Outer membrane protein, 60
Postexposure prophylaxis: *see* Hepatitis B, 682
Poultry: *see* Recombinant vaccines, 4
Pre-immunization: Model using a peptide with carrier function for vaccination against different pathogens, 512
Primary immunization: Different profiles of the human immune response to primary and secondary immunization with an oral *Salmonella typhi* Ty21a vaccine, 423
Procholeragenoid: Immunogenicity of two formulations of oral cholera vaccines in Thai volunteers, 53
Prophylaxis: Pre-exposure rabies prophylaxis for travellers: are the benefits worth the cost?, 833
Prophylaxis: Postexposure rabies prophylaxis: when the guidelines are not respected, 868
Prophylaxis failure, 868
Protective immunity: Resistance to intravenous inoculation of *Mycobacterium* tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w*, 10
Protein adsorption: *see* Aluminium hydroxyphosphate, 201
Pseudomonas aeruginosa: Clinico-immunological trials of *Pseudomonas aeruginosa* vaccine, 491
Pseudomonas aeruginosa: *see* Oral immunization, 294
Pseudorabies virus: *see* ISCOMs, 648
Purification: *see* Poliomyelitis vaccine, 207

Quil A: *see* ISCOM, 129

Rabies: Effective postexposure treatment of rabies-infected sheep with rabies immune globulin and vaccine, 432
Rabies: *see* Recombinant, 190
Rabies: *see* Interleukin-2, 549
Rabies: *see* Humoral neutralizing antibody, 638
Rabies: *see* Prophylaxis, 833, 868
Rabies immunity in dogs: Immune response to rabies vaccine in Thai dogs: A preliminary report, 627
Rabies immunity in dogs: Immunoglobulin response to rabies virus immunization in dogs, 611
Rabies vaccine antibody response: *see* Abbreviated rabies vaccine schedules, 573
Rabies vaccine: Rabies control in the Republic of the Philippines: benefits and costs of elimination, 581
Rabies virus: *see* Ribonucleoprotein, 134
Recombinant: Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes, 564
Recombinant: Efficacy studies on a canarypox-rabies recombinant virus, 190
Recombinant: Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine, 751
Recombinant: *see* Feline leukaemia virus, 89
Recombinant: *see* Adenovirus, 485
Recombinants: Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens, 303
Recombinant antigen: Physicochemical and immunological characterization of recombinant host-protective antigen (VP2) of infectious bursal disease virus, 715
Recombinant gp120: Studies on the immunogenicity of chinese hamster ovary cell-derived recombinant gp120 (HIV-1 IIIB), 47
Recombinant vaccine: *see* Hepatitis B vaccine, 97, 545
Recombinant vaccines: Recombinant vaccines for poultry, 4
Recombinant vaccinia virus: Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus, 470
Recombinant vaccinia virus: Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection, 194
Respiratory syncytial virus: A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice, 863
Respiratory syncytial virus: *see* Antibody-mediated immune suppression, 185
Revaccination: Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination, 403
Ribonucleoprotein: Immunization of monkeys with rabies ribnonucleoprotein (RNP) confers protective immunity against rabies, 134
Rift Valley fever: Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep, 35
Rift Valley fever virus: Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats, 710
Rotavirus: *see* Genetic reassortants, 334

SIV vaccines: SIV vaccines: current status. The role of the SIV-macaque model in AIDS research, 787
Safety of vaccines: Developments in foot-and-mouth disease vaccines, 75

Salmonella typhi: Immunization with temperature-sensitive mutants of *Salmonella typhi* induces protection in mice, 238
Salmonella typhi: *see* Oral immunization, 877
Salmonella typhimurium: *see Aro* genes, 29
Schistosomiasis: *see* Host–parasite, 379
Scorpion toxin: *see* Liposomes, 907
Secondary immunization: *see* Primary immunization, 423
Semliki Forest virus: Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus, 451
Sheep: *see* Rift Valley fever, 35
Shigella dysenteriae serovar 1 S- and R-form: New trends in the use of $Al(OH)_3$-conjugated endotoxins and their subunits from the S- and R-forms of *Shigella dysenteriae* serovar 1 for model vaccination purposes, 106
Shigella flexneri: *see* Live vaccine, 6
Shigella flexneri: *see* T32-ISTRATI, 358
Shigella flexneri: *see* Pathogenesis, 416
Staphylococcus aureus: *see* Surface proteins, 221
Streptococcus pyogenes: *see* Opsonization, 797
Subunit vaccine: *see* ISCOMs, 648
Surface proteins: Potential for vaccination against infections caused by *Staphylococcus aureus*, 221
Synthetic adjuvant: *see* Anti-tumour immunity, 300
Synthetic peptides: Neutralizing epitopes of human parainfluenza virus type 3 are conformational and cannot be imitated by synthetic peptides, 243
Syphilis: Syphilis vaccine: up-regulation of immunogenicity by cyclophosphamide, Ribi adjuvant, and indomethacin confers significant protection against challenge infection in rabbits, 266

T cell response: Enhancement of *in vivo* and *in vitro* T cell response against measles virus haemagglutinin after its incorporation into liposomes: effect of the phospholipid composition, 340
T–B cell interactions: Secondary *in vitro* B lymphocyte (antibody) response to microbial antigens: use in appraisal of vaccine immunogenicity and cytokine immunoregulation, 170
T32-ISTRATI: Virulence phenotype and genetic characteristics of the T32-ISTRATI *Shigella flexneri* 2a vaccine strain, 358
Temperature-sensitive: *see Salmonella typhi*, 238
Tetanus and diphtheria toxoids: Adverse reactions after injection of adsorbed diphtheria–pertussis–tetanus (DPT) vaccine are not due only to pertussis organisms or pertussis components in the vaccine, 699
Tetanus toxoid: Antibody response of pregnant women to two different adsorbed tetanus toxoids, 369
Tick-born encephalitis: *see* Humoral immunity, 42
Tick-borne encephalitis: *see* Virus particle vaccine, 210
Titre determination: *see* β-propiolactone, 473
Toxoplasma gondii: see ISCOMs, 25
Tuberculosis: *see* Protective immunity, 10
Two-dose vaccination: Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule, 326
Typhoid: Construction of genetically defined double *aro* mutants of *Salmonella typhi*, 810

Urabe strain: *see* Mumps, 840

Vaccine development: *see* HIV vaccines, 781
Vaccine formulation: *see* Safety of vaccines, 75
Vaccines: *see* Lyme disease, 531
Vaccinia recombinant: *see* HCMV, 631
Varicella vaccine: Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies, 643
Varicella vaccine: Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy, 873
Varicella vaccine: *see* Antibody assays, 111
Vibrio cholerae: Amino-terminal domain of the El Tor haemolysin of *Vibrio cholerae* O1 is expressed in classical strains and is cytotoxic, 588
Vibrio cholerae: see Procholeragenoid, 53
Viral hepatitis vaccines: *see* Intradermal, 723
Virus particle vaccine: Protection against European isolates of tick-borne encephalitis virus after vaccination with a new tick-borne encephalitis vaccine, 210
Vitamin A: *see* Adjuvant, 122
Vitamin E: *see* Adjuvants, 204, 273

Whole cell pertussis vaccine: Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal, 843